Epstein Secrets

erse: Meacham, Geoffrey: AMAG Pharmaceuticals (AMAG), Acorda Therapeutics Inc. (ACOR), Agios Pharmaceuticals (AGIO), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Amgen Inc (AMGN), Biogen Idec (BIIB), Celgene (CELG), ChemoCentryx, Inc. (CCXI), Dynavax (DVAX), Enanta Pharmaceuticals (ENTA), Gilead Scien

nces (GILD), Idenix Pharmaceuticals (IDIX), InterMune (ITMN), Ironwood Pharmaceuticals (IRWD), Medivation (MDVN), Merrimack Pharmaceuticals (MACK), NPS Pharmaceuticals (NPSP), Ophthotech (OPHT), PTC Therapeutics (PTCT), Regeneron Pharmaceuticals (REGN), Synageva 13ioPluuma (GEVA), United Therapeutics (UTIIR), Verte

ally owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Akebia Therapeutics Inc. Alnylam Pharmaceuticals, AMAG Pharmaceuticals. Inc.. Auxilium Pharmaceuticals. Cubist Pharmaceuticals Inc., GW Pharmaceuticals PLC. Idenix Pharmaceuticals. Inc., ImmunoGen

te Corporation. Infinity Pharmaceuticals Inc. InterMune. Ironwood Pharmaceuticals, Inc., Lexicon Pharmaceuticals. Inc.. Neurocrine Biosciences Inc. NPS Pharmaceuticals, Ophthotech Corp. Pharmacydics Inc.. Portola Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc., Relypsa, Inc.. Synageva Biopharma Corp, Theravance

ally owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Akebia Therapeutics Inc. Alnylam Pharmaceuticals, AMAG Pharmaceuticals. Inc.. Auxilium Pharmaceuticals. Cubist Pharmaceuticals Inc., GW Pharmaceuticals PLC. Idenix Pharmaceuticals. Inc., ImmunoGen

cyte Corporation, Infinity Pharmaceuticals Inc. InterMune. Ironwood Pharmaceuticals, Inc. Lexicon Pharmaceuticals. Inc., Neurocrine Biosciences Inc, NPS Pharmaceuticals, Ophthotech Corp. Pharmacyclics Inc.. Portola Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc., Relypsa. Inc.. Synageva Biopharma Corp, Theravanc